Last reviewed · How we verify
r-hCG
r-hCG is a recombinant human chorionic gonadotropin used to stimulate ovulation and treat infertility.
r-hCG is a recombinant human chorionic gonadotropin used to stimulate ovulation and treat infertility. Used for Induction of ovulation and pregnancy in infertile women who do not ovulate.
At a glance
| Generic name | r-hCG |
|---|---|
| Also known as | Ovitrelle or Ovidrel |
| Sponsor | Dong-A Pharmaceutical Co., Ltd. |
| Drug class | gonadotropin |
| Target | LH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
r-hCG works by mimicking the action of luteinizing hormone, which stimulates the release of an egg from the ovary. This is typically used in conjunction with other fertility treatments. The exact mechanism of action is not fully understood, but it is thought to involve the stimulation of follicle growth and ovulation.
Approved indications
- Induction of ovulation and pregnancy in infertile women who do not ovulate
Common side effects
- Ovarian hyperstimulation syndrome
- Multiple pregnancy
- Abdominal pain
- Nausea and vomiting
- Headache
Key clinical trials
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Assessing the Convenience of Natural Proliferative Phase Frozen Embryo Transfer
- FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles (NA)
- Intravenous Immunoglobulin and Prednisolone for RPL After ART. (PHASE2)
- Natural Cycle vs Programmed Cycle Frozen Embryo Transfer (NA)
- Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders (EARLY_PHASE1)
- Personalizing Window of Implantation During Frozen Embryo Transfer (NA)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |